Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07310758
PHASE2/PHASE3

Contrast-enhanced Ultrasound for Sentinel Node Detection

Sponsor: The Netherlands Cancer Institute

View on ClinicalTrials.gov

Summary

This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \& neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.

Official title: Contrast-enhanced Ultrasound for Sentinel Node Detection in Patients With Melanoma, Breast Cancer or Head & Neck Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

91

Start Date

2025-09-18

Completion Date

2026-09-18

Last Updated

2025-12-30

Healthy Volunteers

No

Interventions

DRUG

Sonazoid

Intradermal injection of the ultrasound contrast agent Sonazoid.

Locations (1)

Netherlands Cancer Institute

Amsterdam, North Holland, Netherlands